透明度(行为)
数据质量
数据完整性
质量保证
质量(理念)
过程管理
数据治理
数据收集
业务
类型学
基石
公司治理
1998年数据保护法
校长(计算机安全)
制药工业
风险分析(工程)
系统回顾
良好制造规范
协议(科学)
数据提取
最佳实践
知识管理
会计
数据共享
质量管理
医药制造业
计算机科学
信息治理
文档
数据科学
监管事务
监管科学
作者
Meryem Chennaq,Marc Lare Sulikoi,Z Aliat,Ihsane Hmamouchi,Younes Rahali
标识
DOI:10.1016/j.pharma.2026.11.003
摘要
BACKGROUND: Data integrity (DI) has become a central pillar of pharmaceutical quality assurance and a recurrent focus of regulatory inspections worldwide. Despite mature guidance, DI deficiencies remain among the most frequently cited inspection observations in good-practice (GxP) environments. This systematic review aimed to identify, analyse and synthesise the regulatory expectations and quality practices governing DI in pharmaceutical laboratories. METHODS: Following the PRISMA 2020 framework, scientific databases and regulatory repositories (FDA, EMA, MHRA, WHO, PIC/S), together with authoritative technical sources, were searched for publications issued between 2002 and 2025. Records were screened in two stages against predefined criteria, and retained studies analysed through structured narrative synthesis. Seventy-six studies were included. RESULTS: Studies converged on four domains: (i) regulatory frameworks and DI governance, built on ALCOA/ALCOA+ principles and a convergent cross-jurisdictional stance; (ii) operational laboratory practices and risk factors, with quality control laboratories the most vulnerable; (iii) digital transformation and Pharma 4.0 technologies, including validated computerised systems, cloud, artificial intelligence and blockchain; and (iv) violations and organisational determinants, where weak quality culture and inadequate oversight emerged as decisive root causes. CONCLUSION: DI is not solely technical or documentary but a systemic, cultural attribute of the quality system, requiring governance, risk-based controls, validated infrastructure and leadership commitment.
科研通智能强力驱动
Strongly Powered by AbleSci AI